Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said ...

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...

Mallinckrodt and Endo are exploring a potential merger that could be valued at about $7 billion, person familiar with the ...

Endo (NDOI) stock gains as the company is in pact with Mallinckrodt (MNKTQ) to merge in a $6.7B deal, creating a Dublin-based ...

The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...

The combination of Mallinckrodt and Endo will create a strong pharmaceutical company with a diversified portfolio, enhanced ...